drugset / Trial / NCT03741933

Apremilast and Moderate to Severe Chronic Hand Dermatitis

NCT03741933

NaSingle-groupOpen-labelTreatment

Summary

Investigators have designed a pilot study involving chronic hand dermatitis (CHD) patients who attend the dermatology clinic at the George Washington Medical Faculty Associates (GW MFA) in order to assess the efficacy and safety of apremilast treatment for the treatment of moderate to severe CHD.

Timeline

Start
2019-02-28
Primary completion
2019-08-01
Completion
2019-08-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Apremilast Small molecule 30 mg

Indications